Form 4: Gilead Sciences Executive Reports Routine Stock Transactions Following RSU Vesting

Diane E. Wilfong, Interim Corporate Controller and CAO of Gilead Sciences, Inc., reported the acquisition of common stock through the vesting of restricted stock units and a subsequent sale to cover tax obligations.

Summary

• Diane E. Wilfong, Interim Corporate Controller and CAO of Gilead Sciences, Inc. (GILD), reported transactions involving the company's common stock.
• On June 10, 2025, Ms. Wilfong acquired 920 shares of common stock through the exercise of restricted stock units (RSUs).
• Following this acquisition, her direct beneficial ownership of common stock increased to 46,016 shares.
• Concurrently, on June 10, 2025, Ms. Wilfong disposed of 340 shares of common stock at a price of $110.09 per share. This disposition was made to cover tax liabilities associated with the RSU vesting.
• After the disposition, her direct beneficial ownership of common stock was 45,676 shares.
• The transaction also reflects the disposition of 920 restricted stock units, leaving 8,785 RSUs beneficially owned.
• Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• The restricted stock units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and the balance vesting 6.25% quarterly thereafter until fully vested.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a routine insider transaction involving the vesting of restricted stock units and a subsequent sale to cover tax liabilities, which is a common and expected event for executive compensation.

Positives

• The acquisition of 920 shares of common stock indicates the vesting of previously granted restricted stock units, representing a form of compensation for the executive.
• The executive's continued beneficial ownership of 45,676 common shares and 8,785 restricted stock units aligns her interests with those of shareholders.

Negatives

• A disposition of 340 shares of common stock occurred, although this was explicitly stated as being for the purpose of covering tax liabilities related to the RSU vesting, which is a common and expected practice.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of restricted stock units and a subsequent sale to cover tax obligations. Such transactions are common across all industries for executives receiving equity compensation and do not reflect broader industry trends or specific competitive dynamics for the pharmaceutical or biotechnology sector.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not indicate a significant change in the company's financial health or strategic direction. The sale of shares for tax purposes is a common practice and not indicative of a lack of confidence.
• Employees: The vesting of RSUs demonstrates the company's ongoing equity compensation practices for its executives.

Key Dates

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, Executive Compensation, Common Stock, Tax Withholding, Diane E. Wilfong